Free Trial

Lyra Therapeutics (LYRA) Earnings Date, Estimates & Call Transcripts

Lyra Therapeutics logo
$7.17 -0.12 (-1.65%)
As of 03:12 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Lyra Therapeutics Earnings Summary

Lyra Therapeutics posted Q2 2025 earnings on August 12, 2025, reporting an EPS of -$5.51, which topped analysts' consensus estimates of -$5.79 by $0.28. Quarterly revenue was reported to be $0.29 million, above the consensus estimate of $0.18 million. With a trailing EPS of -$29.01, Lyra Therapeutics' earnings are expected to grow next year, from ($0.93) to ($0.58) per share.

Latest Q2
Earnings Date
Aug. 12Estimated
Consensus EPS
(Aug. 12)
-$5.79
Actual EPS
(Aug. 12)
-$5.51 Beat By $0.28
Actual Revenue
(Aug. 12)
$0.29M

Q2 2025 Earnings Resources

Get Lyra Therapeutics Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Lyra Therapeutics and other key companies, straight to your inbox.

Sign Up
Skip Charts & View Estimated and Actual Earnings Data

LYRA Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

LYRA Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Lyra Therapeutics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20251-$6.00-$6.00-$6.00
Q2 20252-$7.03-$6.00-$6.52
Q3 20252-$8.87-$6.00-$7.44
Q4 20252-$11.17-$8.00-$9.59
FY 2025 7 -$33.07 -$26.00 -$29.54
Q1 20261-$1.36-$1.36-$1.36
Q2 20261-$1.54-$1.54-$1.54
Q3 20261-$1.63-$1.63-$1.63
Q4 20261-$1.73-$1.73-$1.73

Lyra Therapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails
8/12/2025Q2 2025-$5.79-$5.51+$0.28-$5.51$0.18M$0.29M
5/6/2025Q1 2025-$7.50-$6.00+$1.50-$0.13$0.16M$0.18M
3/13/2025Q4 2024-$6.00-$8.00 -$2.00-$0.16$0.21M$0.21M
8/14/2024Q2 2024-$17.00-$14.50+$2.50$0.16$0.43M$0.60M
4/30/2024Q1 2024-$13.00-$17.50 -$4.50-$0.35$0.40M$0.53M
3/21/2024Q4 2023-$16.50-$11.00+$5.50-$0.22$0.52M$0.15M
11/7/2023Q3 2023-$16.50-$13.50+$3.00-$0.27$0.48M$0.54M

Lyra Therapeutics Earnings - Frequently Asked Questions

Lyra Therapeutics (NASDAQ:LYRA) last announced its quarterly earning data on Tuesday, August 12, 2025. Learn more on LYRA's earnings history.

In the previous quarter, Lyra Therapeutics (NASDAQ:LYRA) reported ($5.51) earnings per share (EPS) to beat the analysts' consensus estimate of ($5.79) by $0.28. Learn more on analysts' earnings estimate vs. LYRA's actual earnings.

Lyra Therapeutics (NASDAQ:LYRA) has a recorded annual revenue of $1.53 million.

Lyra Therapeutics (NASDAQ:LYRA) has a recorded net income of -$93.43 million. LYRA has generated -$29.01 earnings per share over the last four quarters.

Lyra Therapeutics' earnings are expected to grow from ($0.93) per share to ($0.58) per share in the next year.

More Earnings Resources from MarketBeat



This page (NASDAQ:LYRA) was last updated on 8/14/2025 by MarketBeat.com Staff
From Our Partners